Glucose Health, Inc.
Corporate Update
BENTONVILLE, AR --
March 24, 2022 -- InvestorsHub NewsWire -- Glucose Health,
Inc. (OTC:
GLUC) ("Company") today provided the following corporate
update, in response to requests from shareholders and interested
parties for clarification of recent corporate events.
John Fieldly, the
current Chief Executive Officer of Celsius Holdings, Inc.
(Celsius), Hal Kravitz, a current member of the Board of Directors
of Celsius, and Gerry David, the former Chief Executive Officer of
Celsius, comprised the independent members of the Board of
Directors of Glucose Health, Inc. The Company was honored that
current and former executives of a NASDAQ listed company with a
highly successful beverage brand, served on its
Board.
The Company was not
aware, and most importantly, was never informed by Mr. Fieldly or
Mr. Kravitz, that Celsius faced an investigation by the Securities
and Exchange Commission's Division of Enforcement, for possible
violations of securities laws. After obtaining legal advice,
Glucose Health, Inc. requested in writing, and received, their
resignations. Following a period of reflection, Mr. David
voluntarily submitted his resignation.
All warrants granted
to the three directors have been cancelled by Glucose Health, Inc.
In total, 1,800,000 shares of common stock underlying
these warrants have been striken from the Company's fully
diluted share count, which now stands at 20,338,632,
reduced from 22,138,632.
About Glucose Health, Inc.
(OTC: GLUC)
Manufactured by
Glucose Health, Inc., the GLUCODOWN® brand is defining a new
beverage industry category – functional, diabetic friendly,
beverages. By specializing in producing healthy and delicious
beverages, nutritionally appropriate1 for
the nation's 100+ million2 pre
and Type-2 diabetics, and additionally in 2022, launching a new
healthy and delicious ready-to-drink beverage formulated to meet
the nutritional needs of 45+ consumers, Glucose Health, Inc. is
uniquely positioned among all emerging beverage companies in
America.
For more news visit www.glucosehealthinc.com
Like us on Facebook
at www.facebook.com/glucodown
1 For
citations visit www.glucodown.com/clinical-data
2 National
Diabetes Statistics Review, 2020;
Centers for Disease Control and Prevention, Department of Health
and Human Services
Contact:
Murray
Fleming
Glucose
Health, Inc.
info@glucosehealthinc.com
(479)
802-3827
This news release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and while Glucose
Health, Inc. is not subject to the 1934 Securities and Exchange
Act, contains forward-looking statements within the meaning Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,
"possible," "probable, "believes," "seeks," "may, "will, "should,"
"could" or the negative of such terms or other similar expressions.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in the
Company's business. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and the Company
undertakes no obligation to revise or update this release to
reflect events or circumstances after the date hereof.